v3.26.1
Equity Incentive Plans (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Jun. 16, 2023
Jan. 20, 2017
Mar. 31, 2026
Dec. 31, 2025
Mar. 31, 2025
Dec. 31, 2025
Dec. 15, 2025
Dec. 14, 2025
Jul. 02, 2024
Jun. 16, 2022
Options                    
Outstanding balance at the beginning of the period (in shares)     3,757,238              
Outstanding balance at the end of the period (in shares)     3,757,238 3,757,238   3,757,238        
Options exercisable at the end of the period (in shares)     2,620,562              
Options vested and expected to vest at end of period (in shares)     3,757,238              
Weighted Average Exercise Price Per Share                    
Outstanding balance at the beginning of the period (in dollars per share)     $ 7.46              
Outstanding balance at the end of the period (in dollars per share)     7.46 $ 7.46   $ 7.46        
Options exercisable at the end of the period (in dollars per share)     10.06              
Options vested and expected to vest at end of the period (in dollars per share)     $ 7.46              
Weighted Average Remaining Life in Years                    
Outstanding balance     7 years 10 days     7 years 3 months 10 days        
Options exercisable at end of period     6 years 3 days              
Options vested and expected to vest at end of the period     7 years 10 days              
Expiration period     10 years              
Unrecognized compensation cost related to non-vested stock options     $ 1,336              
Company's common stock, par value (in dollars per share)     $ 0.001 $ 0.001   $ 0.001        
Minimum                    
Weighted Average Remaining Life in Years                    
Vesting period     3 years              
Maximum                    
Weighted Average Remaining Life in Years                    
Vesting period     4 years              
Weighted Average                    
Weighted Average Remaining Life in Years                    
Weighted average period for recognition of compensation cost     1 year 5 months 19 days              
Options to purchase common stock                    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                    
Stock Based Compensation Expense     $ 2,131   $ 1,204          
Options to purchase common stock | Research and development                    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                    
Stock Based Compensation Expense         634          
Options to purchase common stock | General and administrative                    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                    
Stock Based Compensation Expense     2,131   $ 570          
Restricted stock units to purchase common stock                    
Weighted Average Remaining Life in Years                    
Vested     17,850              
Unrecognized compensation costs related to RSUs granted to employees     $ 15,778              
Unrecognized costs weighted-average period     2 years 6 months 10 days              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]                    
Outstanding at the beginning     18,305,221              
Settled by the issuance of common stock (in shares)     (1,623,250)              
Granted (in shares)     0 0            
Outstanding at the end     16,681,971 18,305,221   18,305,221        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                    
Outstanding at beginning( in dollars per share)     $ 1.05              
Settled by the issuance of common stock (in dollars per share)     0.87              
Outstanding at end(in dollars per share)     $ 1.07 $ 1.05   $ 1.05        
2016 Plan                    
Weighted Average Remaining Life in Years                    
Annual increase in authorized shares (as a percent)   4.00%                
2016 and 2022 Plan                    
Weighted Average Remaining Life in Years                    
Number of options or stock awards available for grant under the Plan     12,698,368              
2022 Plan                    
Weighted Average Remaining Life in Years                    
Number of options or stock awards available for grant under the Plan                   750,000
Shares reserved for issuance                 2,000,000  
Additional shares issuable 2,250,000                  
2025 Plan                    
Weighted Average Remaining Life in Years                    
Number of options or stock awards available for grant under the Plan             31,454,785      
Company's common stock, par value (in dollars per share)             $ 0.001      
Company increased authorized shares             500,000,000 250,000,000    
2025 Plan | Common stock                    
Weighted Average Remaining Life in Years                    
Company increased authorized shares             490,000,000